Developer docs
API playgroundTry for free, no card

Search company profiles

BillionToOne

Full company profile

uuid000029h

Namestring
BillionToOne
Legal namestring
BillionToOne, Inc.
Company typeenum
Public
Founded yearint
2016
Descriptiontext

BillionToOne, Inc. is a publicly traded precision diagnostics company (NASDAQ: BLLN) headquartered in Menlo Park, California, founded in 2016 by Oguzhan Atay, PhD, and David Tsao, PhD. The company operates two CLIA-certified, CAP-accredited laboratories (Union City, CA for prenatal; Menlo Park, CA for oncology) and is building a third site in Austin, Texas. Its core technology is the patented Quantitative Counting Templates (QCT) molecular counting platform — described as the only multiplex technology that accurately counts DNA molecules at the single-molecule level — which powers a single-molecule NGS (smNGS) workflow for cell-free DNA analysis.

The company's commercial portfolio spans two franchises built on the QCT/smNGS chemistry. The UNITY prenatal franchise offers UNITY Complete (the first NIPT to assess fetal risk for up to 14 recessive and X-linked conditions plus aneuploidies from a single maternal blood draw), UNITY Fetal Antigen NIPTs (red blood cell and platelet antigens, the latter a first-and-only U.S. non-invasive test for FNAIT), and the newly launched Unity Confirm fetal cell-based confirmation test using proprietary Fetal Cell Capture technology. The Northstar oncology franchise offers Northstar Select (an 84-gene comprehensive genomic profiling liquid biopsy detecting SNVs/indels at VAF as low as 0.15%), Northstar Response (a methylation-based treatment response monitoring assay), and add-on modules Northstar PGx and Northstar Select CH. UNITY is used in approximately 1 in 11 U.S. births, and BillionToOne holds roughly 15% of the U.S. prenatal screening market.

BillionToOne generates revenue primarily through per-test diagnostic fees billed to patients, commercial payers, and Medicare. Tests are ordered by healthcare providers (OB/GYNs, MFM specialists, oncologists) via a direct field sales motion and increasingly through Epic's Aura diagnostics suite; reimbursement is supported by Medicare coverage for Northstar Select (MolDx) and an in-network UnitedHealthcare agreement effective April 1, 2026. FY2025 revenue reached $305.1 million (doubling from $152.6 million in FY2024) with 70% gross margins and positive GAAP operating income; the company completed a $314 million Nasdaq IPO in November 2025 at a $4.4 billion valuation and has guided FY2026 revenue to $450-460 million.

Short descriptiontext

BillionToOne is a publicly-traded precision diagnostics company that uses its proprietary QCT molecular counting platform to deliver non-invasive prenatal tests (UNITY) and oncology liquid biopsies (Northstar) from a single blood draw to OB/GYNs, maternal-fetal medicine specialists, and oncologists across the United States and Japan.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive prenatal testing, liquid biopsy diagnostics, molecular diagnostics, cell-free DNA testing, oncology genomic profiling
Industry3 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Test Fees (Prenatal)
TypeTransaction Fee
Description

Per-test revenue from UNITY Complete and other prenatal non-invasive prenatal tests (NIPT). Revenue recognized when tests are processed in the company's CLIA-certified, CAP-accredited laboratories. Tests are ordered by healthcare providers and billed to patients, insurance carriers, or institutional payers. Achieved 15% market share of the estimated $2 billion-plus U.S. prenatal screening market.

billiontoone.com
2Diagnostic Test Fees (Oncology Liquid Biopsy)
TypeTransaction Fee
Description

Per-test revenue from Northstar Select, Northstar Response, and add-on applications (Northstar PGx, Northstar Select CH). Medicare coverage achieved for Northstar Select via Palmetto GBA/MolDx, and in-network agreement with UnitedHealthcare effective April 1, 2026. Targets the $50 billion-plus oncology testing addressable market.

kalkinemedia.com
3Payer Reimbursement
TypeUsage Based
Description

Revenue from third-party payers including Medicare (CMS) and commercial insurers such as UnitedHealthcare. Reimbursement progress has been a key driver of price target upgrades (e.g., Guggenheim raised target to $120 on reimbursement progress).

investing.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Per-test pricing for clinical laboratory diagnostic tests; quote-based, not publicly disclosed
ModelOther
Notes

Not publicly disclosed; pricing depends on payer contracts (Medicare, commercial insurance, self-pay). UNITY Complete covers up to 14 recessive and X-linked conditions, aneuploidies. Northstar Select is an 84-gene liquid biopsy panel.

billiontoone.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1UNITY
Description

Prenatal non-invasive prenatal testing (NIPT) product line including Unity Complete, Unity Screen (UNITY Aneuploidy Screen), Unity Confirm, and Unity Fetal Antigen NIPTs for assessing aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw.

billiontoone.com
+1 more record
Core offering1 text field

BillionToOne develops, validates, and performs proprietary clinical laboratory diagnostic tests that use cell-free DNA and its patented Quantitative Counting Templates (QCT™) molecular counting platform to deliver non-invasive prenatal screening (UNITY Complete and related fetal antigen NIPTs), non-invasive circulating fetal cell-based confirmation (UNITY Confirm), and oncology liquid biopsy tests (Northstar Select comprehensive genomic profiling and Northstar Response treatment-response monitoring). Tests are processed in the company's CLIA-certified, CAP-accredited laboratories in Union City, California (prenatal) and Menlo Park, California (oncology), and are ordered by healthcare providers and reimbursed through patients, commercial insurers, and Medicare.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 100% concordance with invasive diagnostic results across 16 samples in Unity Confirm clinical validation
+9 more records
Product overview1 text field

BillionToOne offers a single underlying molecular counting platform (QCT™ / smNGS) that powers two product families addressing two clinical segments. On the prenatal side, the Unity franchise (Unity Complete / Unity Aneuploidy Screen, the expanded Unity Fetal Antigen NIPTs for RBC and platelet antigens, and the newly launched Unity Confirm fetal-cell-based confirmation test) delivers non-invasive prenatal screening and now diagnostic-grade confirmation from a single maternal blood draw. On the oncology side, the Northstar franchise (Northstar Select comprehensive genomic profiling liquid biopsy and Northstar Response methylation-based treatment-response monitoring, plus add-ons Northstar PGx and Northstar Select CH) uses the same QCT smNGS chemistry to guide therapy selection and monitor response from a single blood draw. Both product families are supported by a CAP-accredited, CLIA-certified laboratory network in Union City, CA (prenatal) and Menlo Park, CA (oncology) and are integrated into Epic's Aura diagnostics suite for in-EHR ordering and result delivery.

Product and service6 records
1Unity Complete
CategoryPrenatal non-invasive prenatal testing (NIPT)
Description

Unity Complete® is the first non-invasive prenatal test (NIPT) to use cfDNA to assess fetal risk for up to 14 recessive and X-linked conditions, aneuploidies, and fetal antigens from a single maternal blood sample at 9+ weeks of pregnancy; it does not require a paternal blood sample.

2Unity Confirm
CategoryPrenatal diagnostic confirmation testing
Description

Unity Confirm™ is a non-invasive circulating fetal cell-based prenatal confirmation test that uses BillionToOne's Fetal Cell Capture™ technology (multi-step immunological enrichment, single-cell isolation, and whole genome sequencing) to provide diagnostic-level insights for high-risk UNITY Aneuploidy Screen results without invasive procedures; demonstrated 100% concordance with invasive diagnostics across 16 samples.

3UNITY Expanded Red Blood Cell Fetal Antigen NIPT
CategoryPrenatal fetal antigen screening
Description

UNITY's expanded Red Blood Cell Fetal Antigen NIPT determines fetal antigen status across approximately 99% of antigens associated with hemolytic disease of the fetus and newborn (HDFN); available exclusively through the UNITY Aneuploidy Screen with no additional blood draw.

4UNITY Platelet Fetal Antigen NIPT
CategoryPrenatal fetal antigen screening
Description

The first-and-only non-invasive prenatal test in the U.S. for determining fetal platelet antigen status in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition that can cause severe neonatal thrombocytopenia and intracranial hemorrhage.

5Northstar Select
CategoryOncology liquid biopsy - comprehensive genomic profiling
Description

Northstar Select® is an ultra-sensitive 84-gene single-molecule NGS comprehensive genomic profiling (CGP) liquid biopsy assay for therapy selection in patients with advanced solid tumors; detects SNVs and indels at variant allele frequencies as low as 0.15% (95% LoD) and is delivered with a 5-day average turnaround time.

6Northstar Response
CategoryOncology liquid biopsy - treatment response monitoring
Description

Northstar Response® is a tissue-free, methylation-based pan-cancer assay that monitors treatment response by measuring changes in circulating tumor-derived signals over time with single-molecule precision, often months ahead of imaging.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-01
Description

Signed in-network agreement with UnitedHealthcare effective April 1, 2026. Improves patient access to BillionToOne tests and increases test prices for UnitedHealthcare-insured patients. Announced alongside Q4 2025 earnings results on March 4, 2026. Expands commercial insurance coverage footprint.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Collaboration to integrate BillionToOne's prenatal (UNITY Complete) and oncology testing portfolio (Northstar Select, Northstar Response) with Epic's Aura diagnostics suite. Agreement signed December 2025, announced January 15, 2026. Epic is described as 'the nation's most widely used comprehensive electronic health record.' Clinicians can order BillionToOne tests directly within Epic; discrete results flow back into EHR and MyChart patient portal. Quote from Seth Hain (SVP R&D, Epic): 'BillionToOne's use of Aura integrates oncology and prenatal tests and results where they matter—inside the clinician's workflow, at the moment of decision.'

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

BillionToOne's Northstar Select® liquid biopsy test was selected as the new liquid biopsy for the LC-SCRUM-TRY nationwide multi-center study in Japan. The study analyzes approximately 2,000 clinical specimens from patients with advanced or recurrent NSCLC. Selected after demonstrating higher sensitivity than a previously used assay in head-to-head validation against paired tumor tissue and plasma samples from ~1,000 patients. Quote from Koichi Goto, MD, PhD (Deputy Director, NCCHE). Northstar Select detection at VAF as low as 0.15% (95% LoD) was a key differentiator.

Strategic tierModerateTypeOthersAnnounced on2025-11-01
Description

Represented BillionToOne Inc. in its $314M IPO completed November 7, 2025. Shares surged 82% on first trading day. Legal counsel for IPO transaction.

Strategic tierModerateTypeOthersAnnounced on2025-11-01
Description

Represented long-time client BillionToOne in its upsized $273.1 million IPO, which began trading on the Nasdaq on November 6, 2025. Issued 4.6 million shares at $60 each.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Northstar Select® met Medicare coverage criteria established by Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDx), following rigorous review of evidence demonstrating analytical validity, clinical validity, and clinical utility. Helps ensure more patients with advanced cancer can benefit from personalized treatment approaches.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership mentioned in CEO Oguzhan Atay's Founders Letter with the potential to enable a therapy for hemolytic disease in fetuses and newborns (HDFN), a high-risk condition that can result in fetal death. Strategic collaboration in prenatal therapeutics area.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Natera is the most direct competitor to BillionToOne's UNITY prenatal NIPT franchise (Vistara, Panorama) and is also a major oncology testing player (Signatera MRD). Both companies serve OB/GYNs, MFMs, and oncologists with cfDNA-based tests and compete head-to-head for the same U.S. prenatal market share BillionToOne now claims 15% of.

TypeDirect peer
Description

Guardant Health is a leading liquid biopsy competitor to BillionToOne's Northstar Select, offering Guardant360 CDx for comprehensive genomic profiling in advanced solid tumors. Both companies target oncologists with cfDNA-based CGP tests and compete for Medicare MolDx coverage and pharma partnerships.

TypeDirect peer
Description

NeoGenomics is a CLIA-certified oncology diagnostics laboratory offering solid tumor and liquid biopsy profiling, including its RaDaR MRD assay. It is a direct comparable as a clinical lab services provider in oncology competing for the same oncologist relationships and reimbursement pathways.

TypeDirect peer
Description

Veracyte is a genomic diagnostics company offering Afirma (thyroid), Decipher Prostate, and Prosigna breast cancer tests. It is comparable to BillionToOne as a specialty molecular diagnostics company targeting oncologists with tissue and blood-based genomic tests for therapy selection.

TypeBroad incumbent
Description

Exact Sciences is a larger molecular diagnostics incumbent offering Cologuard (colorectal cancer screening) and the Oncotype DX franchise for oncology therapy selection. It is a broad incumbent in the same genomic diagnostics space BillionToOne operates in, with much larger scale and broader payor coverage.

TypeBroad incumbent
Description

Myriad Genetics is an established genetic testing incumbent offering hereditary cancer (BRACAnalysis), prenatal (Prequel, Foresight), and oncology tests. It is comparable to BillionToOne as a diversified genetic diagnostics company serving OB/GYNs and oncologists, though with a broader legacy test portfolio.

7Tempus AI
TypeDirect peer
Description

Tempus AI offers comprehensive genomic profiling (xT, xR), liquid biopsy (xF), and AI-enabled precision medicine solutions to oncologists. It is a direct comparable as a technology-forward precision oncology diagnostics competitor with overlapping products and target customers.

TypeEmerging player
Description

Personalis is a smaller cancer genomics competitor offering NeXT Personal (tumor-informed MRD) and other ultra-sensitive ctDNA tests. It is comparable to BillionToOne's Northstar Response for treatment response monitoring, though with a narrower oncology-only focus and smaller commercial scale.

TypeBroad incumbent
Description

Foundation Medicine, owned by Roche, offers FoundationOne CDx (tissue CGP) and FoundationOne Liquid CDx, the entrenched tissue-and-blood CGP incumbents in oncology. It is a broad incumbent that BillionToOne's Northstar Select must displace in academic and community oncology settings.

TypeEmerging player
Description

Adaptive Biotechnologies offers clonoSEQ (MRD) and immune repertoire sequencing for oncology and immune-driven diseases. It is comparable to BillionToOne as an emerging molecular diagnostics company applying novel genomic platforms (immunosequencing vs. QCT molecular counting) to clinical oncology use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors31 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BillionToOne

Molecular Diagnosticsbilliontoone.com

BillionToOne is a publicly-traded precision diagnostics company that uses its proprietary QCT molecular counting platform to deliver non-invasive prenatal tests (UNITY) and oncology liquid biopsies (Northstar) from a single blood draw to OB/GYNs, maternal-fetal medicine specialists, and oncologists across the United States and Japan.

What BillionToOne does

BillionToOne, Inc. is a publicly traded precision diagnostics company (NASDAQ: BLLN) headquartered in Menlo Park, California, founded in 2016 by Oguzhan Atay, PhD, and David Tsao, PhD. The company operates two CLIA-certified, CAP-accredited laboratories (Union City, CA for prenatal; Menlo Park, CA for oncology) and is building a third site in Austin, Texas. Its core technology is the patented Quantitative Counting Templates (QCT) molecular counting platform — described as the only multiplex technology that accurately counts DNA molecules at the single-molecule level — which powers a single-molecule NGS (smNGS) workflow for cell-free DNA analysis.

The company's commercial portfolio spans two franchises built on the QCT/smNGS chemistry. The UNITY prenatal franchise offers UNITY Complete (the first NIPT to assess fetal risk for up to 14 recessive and X-linked conditions plus aneuploidies from a single maternal blood draw), UNITY Fetal Antigen NIPTs (red blood cell and platelet antigens, the latter a first-and-only U.S. non-invasive test for FNAIT), and the newly launched Unity Confirm fetal cell-based confirmation test using proprietary Fetal Cell Capture technology. The Northstar oncology franchise offers Northstar Select (an 84-gene comprehensive genomic profiling liquid biopsy detecting SNVs/indels at VAF as low as 0.15%), Northstar Response (a methylation-based treatment response monitoring assay), and add-on modules Northstar PGx and Northstar Select CH. UNITY is used in approximately 1 in 11 U.S. births, and BillionToOne holds roughly 15% of the U.S. prenatal screening market.

BillionToOne generates revenue primarily through per-test diagnostic fees billed to patients, commercial payers, and Medicare. Tests are ordered by healthcare providers (OB/GYNs, MFM specialists, oncologists) via a direct field sales motion and increasingly through Epic's Aura diagnostics suite; reimbursement is supported by Medicare coverage for Northstar Select (MolDx) and an in-network UnitedHealthcare agreement effective April 1, 2026. FY2025 revenue reached $305.1 million (doubling from $152.6 million in FY2024) with 70% gross margins and positive GAAP operating income; the company completed a $314 million Nasdaq IPO in November 2025 at a $4.4 billion valuation and has guided FY2026 revenue to $450-460 million.

BillionToOne firmographics

Firmographics
Name
BillionToOne
Legal name
BillionToOne, Inc.
Website
https://billiontoone.com
Company type
Public
Founded year
2016
Operating status
Ipo
Headcount range
501–1,000 employees
Short description
BillionToOne is a publicly-traded precision diagnostics company that uses its proprietary QCT molecular counting platform to deliver non-invasive prenatal tests (UNITY) and oncology liquid biopsies (Northstar) from a single blood draw to OB/GYNs, maternal-fetal medicine specialists, and oncologists across the United States and Japan.
Ownership category
akta.pro rank

BillionToOne industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Non-invasive prenatal testing
  • Liquid biopsy diagnostics
  • Molecular diagnostics
  • Cell-free DNA testing
  • Oncology genomic profiling

Where BillionToOne is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices4 records

Markets served

BillionToOne business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Diagnostic Test Fees (Prenatal): Per-test revenue from UNITY Complete and other prenatal non-invasive prenatal tests (NIPT). Revenue recognized when tests are processed in the company's CLIA-certified, CAP-accredited laboratories. Tests are ordered by healthcare providers and billed to patients, insurance carriers, or institutional payers. Achieved 15% market share of the estimated $2 billion-plus U.S. prenatal screening market.
  2. Diagnostic Test Fees (Oncology Liquid Biopsy): Per-test revenue from Northstar Select, Northstar Response, and add-on applications (Northstar PGx, Northstar Select CH). Medicare coverage achieved for Northstar Select via Palmetto GBA/MolDx, and in-network agreement with UnitedHealthcare effective April 1, 2026. Targets the $50 billion-plus oncology testing addressable market.
  3. Payer Reimbursement: Revenue from third-party payers including Medicare (CMS) and commercial insurers such as UnitedHealthcare. Reimbursement progress has been a key driver of price target upgrades (e.g., Guggenheim raised target to $120 on reimbursement progress).

Pricing tiers

ModelBillingPrice
Other—Per-test pricing for clinical laboratory diagnostic tests; quote-based, not publicly disclosed

Go-to-market motion5 records

Distribution channels5 records

Marketing channels6 records

BillionToOne product offering

Product offering

Core offering

BillionToOne develops, validates, and performs proprietary clinical laboratory diagnostic tests that use cell-free DNA and its patented Quantitative Counting Templates (QCT™) molecular counting platform to deliver non-invasive prenatal screening (UNITY Complete and related fetal antigen NIPTs), non-invasive circulating fetal cell-based confirmation (UNITY Confirm), and oncology liquid biopsy tests (Northstar Select comprehensive genomic profiling and Northstar Response treatment-response monitoring). Tests are processed in the company's CLIA-certified, CAP-accredited laboratories in Union City, California (prenatal) and Menlo Park, California (oncology), and are ordered by healthcare providers and reimbursed through patients, commercial insurers, and Medicare.

Product overview

BillionToOne offers a single underlying molecular counting platform (QCT™ / smNGS) that powers two product families addressing two clinical segments. On the prenatal side, the Unity franchise (Unity Complete / Unity Aneuploidy Screen, the expanded Unity Fetal Antigen NIPTs for RBC and platelet antigens, and the newly launched Unity Confirm fetal-cell-based confirmation test) delivers non-invasive prenatal screening and now diagnostic-grade confirmation from a single maternal blood draw. On the oncology side, the Northstar franchise (Northstar Select comprehensive genomic profiling liquid biopsy and Northstar Response methylation-based treatment-response monitoring, plus add-ons Northstar PGx and Northstar Select CH) uses the same QCT smNGS chemistry to guide therapy selection and monitor response from a single blood draw. Both product families are supported by a CAP-accredited, CLIA-certified laboratory network in Union City, CA (prenatal) and Menlo Park, CA (oncology) and are integrated into Epic's Aura diagnostics suite for in-EHR ordering and result delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • UNITY: Prenatal non-invasive prenatal testing (NIPT) product line including Unity Complete, Unity Screen (UNITY Aneuploidy Screen), Unity Confirm, and Unity Fetal Antigen NIPTs for assessing aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw.
  • Northstar

Products and services

  • Unity Complete Unity Complete® is the first non-invasive prenatal test (NIPT) to use cfDNA to assess fetal risk for up to 14 recessive and X-linked conditions, aneuploidies, and fetal antigens from a single maternal blood sample at 9+ weeks of pregnancy; it does not require a paternal blood sample.
  • Unity Confirm Unity Confirm™ is a non-invasive circulating fetal cell-based prenatal confirmation test that uses BillionToOne's Fetal Cell Capture™ technology (multi-step immunological enrichment, single-cell isolation, and whole genome sequencing) to provide diagnostic-level insights for high-risk UNITY Aneuploidy Screen results without invasive procedures; demonstrated 100% concordance with invasive diagnostics across 16 samples.
  • UNITY Expanded Red Blood Cell Fetal Antigen NIPT UNITY's expanded Red Blood Cell Fetal Antigen NIPT determines fetal antigen status across approximately 99% of antigens associated with hemolytic disease of the fetus and newborn (HDFN); available exclusively through the UNITY Aneuploidy Screen with no additional blood draw.
  • UNITY Platelet Fetal Antigen NIPT The first-and-only non-invasive prenatal test in the U.S. for determining fetal platelet antigen status in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition that can cause severe neonatal thrombocytopenia and intracranial hemorrhage.
  • Northstar Select Northstar Select® is an ultra-sensitive 84-gene single-molecule NGS comprehensive genomic profiling (CGP) liquid biopsy assay for therapy selection in patients with advanced solid tumors; detects SNVs and indels at variant allele frequencies as low as 0.15% (95% LoD) and is delivered with a 5-day average turnaround time.
  • Northstar Response Northstar Response® is a tissue-free, methylation-based pan-cancer assay that monitors treatment response by measuring changes in circulating tumor-derived signals over time with single-molecule precision, often months ahead of imaging.

Quantifiable outcome

  • 100% concordance with invasive diagnostic results across 16 samples in Unity Confirm clinical validation
  • +9 more outcomes

Companies that use BillionToOne

Customer profile

Named customers2 records

Ideal customer profiles2 records

BillionToOne technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

BillionToOne partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship and moderate.

  • UnitedHealthcareflagshipChannel Partner/ Reseller/ Distributor · 1 March 2026Signed in-network agreement with UnitedHealthcare effective April 1, 2026. Improves patient access to BillionToOne tests and increases test prices for UnitedHealthcare-insured patients. Announced alongside Q4 2025 earnings results on March 4, 2026. Expands commercial insurance coverage footprint.
  • Epic SystemsflagshipTechnology or Integration · 1 December 2025Collaboration to integrate BillionToOne's prenatal (UNITY Complete) and oncology testing portfolio (Northstar Select, Northstar Response) with Epic's Aura diagnostics suite. Agreement signed December 2025, announced January 15, 2026. Epic is described as 'the nation's most widely used comprehensive electronic health record.' Clinicians can order BillionToOne tests directly within Epic; discrete results flow back into EHR and MyChart patient portal. Quote from Seth Hain (SVP R&D, Epic): 'BillionToOne's use of Aura integrates oncology and prenatal tests and results where they matter—inside the clinician's workflow, at the moment of decision.'
  • National Cancer Center Hospital East (NCCHE)flagshipStrategic or Co-development Partner · 1 November 2025BillionToOne's Northstar Select® liquid biopsy test was selected as the new liquid biopsy for the LC-SCRUM-TRY nationwide multi-center study in Japan. The study analyzes approximately 2,000 clinical specimens from patients with advanced or recurrent NSCLC. Selected after demonstrating higher sensitivity than a previously used assay in head-to-head validation against paired tumor tissue and plasma samples from ~1,000 patients. Quote from Koichi Goto, MD, PhD (Deputy Director, NCCHE). Northstar Select detection at VAF as low as 0.15% (95% LoD) was a key differentiator.
  • Greenberg Traurig, LLPmoderateOthers · 1 November 2025Represented BillionToOne Inc. in its $314M IPO completed November 7, 2025. Shares surged 82% on first trading day. Legal counsel for IPO transaction.
  • Gunderson DettmermoderateOthers · 1 November 2025Represented long-time client BillionToOne in its upsized $273.1 million IPO, which began trading on the Nasdaq on November 6, 2025. Issued 4.6 million shares at $60 each.
  • Medicare (CMS) via Palmetto GBA / MolDxflagshipChannel Partner/ Reseller/ Distributor · 1 April 2025Northstar Select® met Medicare coverage criteria established by Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDx), following rigorous review of evidence demonstrating analytical validity, clinical validity, and clinical utility. Helps ensure more patients with advanced cancer can benefit from personalized treatment approaches.
  • Johnson & JohnsonflagshipStrategic or Co-development Partner · 1 January 2025Partnership mentioned in CEO Oguzhan Atay's Founders Letter with the potential to enable a therapy for hemolytic disease in fetuses and newborns (HDFN), a high-risk condition that can result in fetal death. Strategic collaboration in prenatal therapeutics area.

Scale indicators16 records

Recent moves8 records

Expansion highlights5 records

BillionToOne competitors and assessment

Company assessment

Direct peers

  • Natera: Natera is the most direct competitor to BillionToOne's UNITY prenatal NIPT franchise (Vistara, Panorama) and is also a major oncology testing player (Signatera MRD). Both companies serve OB/GYNs, MFMs, and oncologists with cfDNA-based tests and compete head-to-head for the same U.S. prenatal market share BillionToOne now claims 15% of.
  • Guardant Health: Guardant Health is a leading liquid biopsy competitor to BillionToOne's Northstar Select, offering Guardant360 CDx for comprehensive genomic profiling in advanced solid tumors. Both companies target oncologists with cfDNA-based CGP tests and compete for Medicare MolDx coverage and pharma partnerships.
  • NeoGenomics: NeoGenomics is a CLIA-certified oncology diagnostics laboratory offering solid tumor and liquid biopsy profiling, including its RaDaR MRD assay. It is a direct comparable as a clinical lab services provider in oncology competing for the same oncologist relationships and reimbursement pathways.
  • Veracyte: Veracyte is a genomic diagnostics company offering Afirma (thyroid), Decipher Prostate, and Prosigna breast cancer tests. It is comparable to BillionToOne as a specialty molecular diagnostics company targeting oncologists with tissue and blood-based genomic tests for therapy selection.
  • Tempus AI: Tempus AI offers comprehensive genomic profiling (xT, xR), liquid biopsy (xF), and AI-enabled precision medicine solutions to oncologists. It is a direct comparable as a technology-forward precision oncology diagnostics competitor with overlapping products and target customers.

Broad incumbents

  • Exact Sciences: Exact Sciences is a larger molecular diagnostics incumbent offering Cologuard (colorectal cancer screening) and the Oncotype DX franchise for oncology therapy selection. It is a broad incumbent in the same genomic diagnostics space BillionToOne operates in, with much larger scale and broader payor coverage.
  • Myriad Genetics: Myriad Genetics is an established genetic testing incumbent offering hereditary cancer (BRACAnalysis), prenatal (Prequel, Foresight), and oncology tests. It is comparable to BillionToOne as a diversified genetic diagnostics company serving OB/GYNs and oncologists, though with a broader legacy test portfolio.
  • Foundation Medicine (Roche): Foundation Medicine, owned by Roche, offers FoundationOne CDx (tissue CGP) and FoundationOne Liquid CDx, the entrenched tissue-and-blood CGP incumbents in oncology. It is a broad incumbent that BillionToOne's Northstar Select must displace in academic and community oncology settings.

Emerging players

  • Personalis: Personalis is a smaller cancer genomics competitor offering NeXT Personal (tumor-informed MRD) and other ultra-sensitive ctDNA tests. It is comparable to BillionToOne's Northstar Response for treatment response monitoring, though with a narrower oncology-only focus and smaller commercial scale.
  • Adaptive Biotechnologies: Adaptive Biotechnologies offers clonoSEQ (MRD) and immune repertoire sequencing for oncology and immune-driven diseases. It is comparable to BillionToOne as an emerging molecular diagnostics company applying novel genomic platforms (immunosequencing vs. QCT molecular counting) to clinical oncology use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BillionToOne social profiles

Digital presence

BillionToOne compliance and trust

Trust signal

Compliance9 records

BillionToOne financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BillionToOne leadership team

Management profile

Number of profiles

Profiles10 records

BillionToOne funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors31 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BillionToOne M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BillionToOne

What does BillionToOne do?

BillionToOne develops, validates, and performs proprietary clinical laboratory diagnostic tests that use cell-free DNA and its patented Quantitative Counting Templates (QCT™) molecular counting platform to deliver non-invasive prenatal screening (UNITY Complete and related fetal antigen NIPTs), non-invasive circulating fetal cell-based confirmation (UNITY Confirm), and oncology liquid biopsy tests (Northstar Select comprehensive genomic profiling and Northstar Response treatment-response monitoring). Tests are processed in the company's CLIA-certified, CAP-accredited laboratories in Union City, California (prenatal) and Menlo Park, California (oncology), and are ordered by healthcare providers and reimbursed through patients, commercial insurers, and Medicare.

Is BillionToOne a public or private company?

BillionToOne is a public company. It is classified as public and is currently ipo.

When was BillionToOne founded?

BillionToOne was founded in 2016. It employs 501 to 1,000 people.

Where is BillionToOne based?

BillionToOne is headquartered in Menlo Park, United States, in the North America region.

How does BillionToOne make money?

Three revenue lines are on record. Diagnostic Test Fees (Prenatal) is the primary driver. The others are diagnostic Test Fees (Oncology Liquid Biopsy) and payer Reimbursement.

Who are BillionToOne's main competitors?

Direct peers on record are Natera, Guardant Health, NeoGenomics, Veracyte and Tempus AI. Broad incumbents are Exact Sciences, Myriad Genetics and Foundation Medicine (Roche). Emerging players are Personalis and Adaptive Biotechnologies.

Does BillionToOne have an API?

No public API is recorded for BillionToOne.

What industry is BillionToOne in?

BillionToOne's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageLost Money on BillionToOne, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 6.32% Stock DeclineThe Law Offices of Frank R. Cruz is investigating potential securities fraud claims against BillionToOne, Inc. after its stock fell 6.32% on November 18, 2026, following a short report alleging undisclosed Medicaid fraud fines exceeding $1.2 billion. The firm is examining whether the company or executives made false or misleading statements to investors.FinancialContent Business PageRosen Law Firm Encourages BillionToOne, Inc. Investors to Inquire About Securities Class Action Investigation - BLLNRosen Law Firm announced an investigation of potential securities claims against BillionToOne, Inc. over allegedly misleading business information. The firm is preparing a class action seeking recovery of investor losses on a contingency basis. Investors are encouraged to contact the firm for more information.YahooBillionToOne: 3 Key Takeaways for Long-Term InvestorsBillionToOne raised its full-year 2026 revenue guidance to $460-470 million after Q3 revenue of $123 million, up 47% year over year. The company reported GAAP profitability for the fifth consecutive quarter and a 71% gross margin. It plans to launch its tissue-free MRD test, Northstar Clear, on Dec. 15, 2026.The Motley FoolBillionToOne: 3 Key Takeaways for Long-Term InvestorsBillionToOne raised its full-year 2026 revenue guidance to $460-470 million, with Q3 revenue of $123 million, up 47% year over year. The company reported a 71% gross margin and fifth consecutive quarter of GAAP operating income. It plans to launch its tissue-free MRD test, Northstar Clear, on Dec. 15, 2026.Investing.comBillionToOne at Stifel 2026 Healthcare Conference: growth broadensBillionToOne reported $68 million in annualized oncology revenue for Q3 2026, with about 65 sales reps each generating over $1 million. Its prenatal testing is now 90% in-network, opening access to health systems representing 60% of the market. Management expects Medicare coverage for Northstar Response in 2027.Seeking AlphaBillionToOne, Inc. (BLLN) Presents at 2026 UBS Global Healthcare Conference TranscriptBillionToOne CEO Oguzhan Atay presented at the 2026 UBS Global Healthcare Conference, discussing the company's platform differentiation and growth strategy. He highlighted cell-free DNA as a biomarker and the QCT backbone for precise quantification, addressing unmet needs and investment balance.Investing.comBillionToOne at UBS Global Healthcare Conference: growth meets margin disciplineBillionToOne reported Q3 prenatal revenue growth of 42% and oncology clinical testing revenue of $17.1 million, up 96%, with a blended gross margin of 71%. The company's Clear tissue-free MRD test launches December 15, and a 2027 reimbursement increase could lift revenue by about 20%.YahooBillionToOne (BLLN) Stock Looks Cheap Against Future Cash FlowBillionToOne's stock rose 27.6% year to date, closing at $113.94, while a discounted cash flow model estimates intrinsic value above that price. Management raised 2026 revenue guidance and highlighted the Northstar Clear launch, which may support higher future cash flows. The stock's next move depends on whether the current price aligns with its cash-flow-based intrinsic value.American Banking and Market NewsBilliontoone (NASDAQ:BLLN) Given New $135.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase raised its price target on Billiontoone to $135 from $130, keeping an Overweight rating. The stock opened at $112.39, with a consensus price target of $126.88. The company raised its 2026 revenue guidance to $460–$470 million and plans to launch Northstar Clear on December 15.TradingViewJP Morgan maintains BillionToOne at Overweight, raises price target to $135 from $130JP Morgan maintained BillionToOne at Overweight and raised its price target to $135 from $130, a 3.8% increase. The target implies 20.1% upside from the Nov 5 close of $112.39.